

The CFTR gene variants in paediatric nasal polyposis: a study in the Italian population*

Sara Santarsiero¹, Emanuela Sitzia¹, Fabio Majo², Giulia Marini¹, Lorenzo Sinibaldi³, Giovanni Cristalli¹, Renato Cutrera², Alessandro Giovanni Fiocchi⁴, Fabiana Ciciriello⁴, Maria Cristina Artesani⁴

¹ Department of Otorhinolaryngology, Bambino Gesù Children's Hospital IRCCS, Rome, Italy

² Paediatric Pulmonology and Cystic Fibrosis Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy

³ Department of Genetics, Bambino Gesù Children's Hospital IRCCS, Rome, Italy

⁴ Paediatric Allergy and Cystic Fibrosis Research Unit, Bambino Gesù Children's Hospital IRCCS, Rome, Italy

Rhinology 63: 4, 0 - 0, 2025

<https://doi.org/10.4193/Rhin24.568>

***Received for publication:**

December 26, 2024

Accepted: May 4, 2025

Associate Editor:

Sanna Toppila-Salmi

Dear Editor:

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a relatively uncommon condition in the paediatric population, with a prevalence estimated at 0.1–0.8%, compared to approximately 4% in adults^(1,2). The early onset of CRSwNP emphasises the significant role of genetic factors in its pathophysiology⁽³⁾. Approximately 20% of paediatric patients with CRSwNP are associated with systemic genetic disorders, with cystic fibrosis (CF) being the most prevalent⁽²⁾. CF is characterised by a dysfunction of the CF transmembrane conductance regulator (CFTR) protein. Over 2,000 distinct CFTR variants have been identified, resulting in varying organ involvement and disease severity. In 2000, the World Health Organization introduced the term “CFTR-related disorders” (CFTR-RDs) to include clinical entities associated with CFTR dysfunction that do not meet the diagnostic criteria for CF⁽⁴⁾. CFTR-RDs include congenital bilateral absence of the vas deferens (CBAVD), recurrent pancreatitis (RP), and disseminated bronchiectasis (DB). However, recent studies emphasised a significant prevalence of heterozygous CFTR pathogenic variants in paediatric and adult CRSwNP populations without CF^(4–8). We assessed the prevalence of CFTR variants in a paediatric population with CRSwNP.

Detailed methods and results are provided in the Supplementary Material. We included 34 patients aged 5–18 years diagnosed with CRSwNP based on nasal endoscopy and computed tomography findings, excluding those with other known causes of CRSwNP (Table 1). We evaluated patients for CFTR variants, the sweat chloride test (SCT), comorbidities (CFTR-RD and lower airway diseases, including asthma and recurrent bronchitis), and predisposing factors for CRSwNP, including familial risk, cigarette smoke exposure, adenoidal pathology, allergic rhinitis (AR), non-allergic rhinitis (NAR), and gastroesophageal reflux disease (GERD).

In 17 patients (50%), 11 distinct CFTR variants were identified, with c.1210-12T being the most prevalent ($n = 7$)⁽⁵⁾. SCT yielded borderline results in 3 CFTR carriers and negative results in all others. None of the CFTR carriers or their families exhibited CBAVD, RP, and DB. The incidence of asthma in CFTR- carriers was 29.41%, while in CFTR-negative patients it was 11.76%. Our findings support the hypothesis that paediatric CRSwNP patients exhibit a higher prevalence of CFTR variants compared to the general Italian population (3–4%)⁽⁶⁾. Several identified variants are documented in international databases as associated with CFTR-RDs, including some previously reported in CRSwNP (Supplementary Material)^(6–8).

We evaluated potential predisposing factors associated with CRSwNP. A family history of CRSwNP was reported in six CFTR carriers, including three sibling pairs; no parents or other relatives were affected. Nasal endoscopy revealed significantly higher grades of adenoid hypertrophy (grades III and IV) in CFTR-carriers compared to CFTR-negative patients (47.06% vs. 11.76%).

This study has several limitations. First, we did not perform nasal potential difference testing due to its limited availability in specialised centres, rendering it impractical for routine clinical use. Second, the limited number of our sample may have caused a selection bias, therefore the evaluation of the real incidence of CFTRs variants in Italian paediatric CRSwNP requires a larger sample.

In conclusion, screening for CFTR variants is warranted in paediatric patients with CRSwNP. Current diagnostic criteria accept CFTR genotyping as a surrogate marker for CFTR dysfunction^(4,8). Furthermore, single allelic CFTR variants and other cofactors may predispose individuals to CRSwNP^(6–8). Notably, evaluation of siblings of affected children is recommended, regardless of parental carrier status. Asthma, the most common comorbidity,

Table 1. Clinical characteristics of 34 patients with CRSwNP.

Patient's No., age (y), sex	Familiar history of CRSwNP	Cigarette smoke	Predisposing factors/ Comorbidities	AH grade	SCT	CFTR variant(s)
No.1, 13 y, M	No	No	AR, recurrent bronchitis	I	borderline	c.1210-12T[5]
No.2, 9 y, F	No	No	NARMA, recurrent bronchitis	III	negative	c.1210-12T[5]
No.3, 9 y, M	No	No	AR	III	negative	undetected
No.4, 18 y, M	No	No	NARES	I	negative	undetected
No.5, 14 y, M	No	Yes	AR	I	negative	undetected
No.6, 12 y, F	Yes§	No	AR, asthma, GERD	III	negative	c.3322G>C
No.7, 9 y, M	Yes§	No	AR, asthma	III	negative	c.3322G>C; c.3705T>G
No.8, 11 y, F	No	No	NARES, recurrent bronchitis	II	negative	undetected
No.9, 18 y, F	No	Yes	AR, asthma	I	negative	c.91C>T
No.10, 10 y, M	Yes§	No	AR, asthma	III	borderline	c.1210-12T[5]; c.1736A>G
No.11, 5 y, F	Yes§	No	AR, asthma	IV	negative	c.2991G>C
No.12, 16 y, M	No	No	AR	I	negative	undetected
No. 13, 15 y, M	No	No	NARESMA, recurrent bronchitis	I	negative	undetected
No. 14, 16 y, M	No	No	NARESMA	I	negative	undetected
No. 15, 12 y, F	No	Yes	AR	II	negative	undetected
No. 16, 14 y, M	No	No	NARESMA	I	negative	c.91C>T
No. 17, 13 y, M	No	No	AR	I	negative	undetected
No. 18, 18 y, M	No	No	NARESMA	I	negative	c.2900T>C
No. 19, 17 y, M	No	Yes	AR	I	negative	undetected
No. 20, 14 y, F	No	No	NARESMA	II	negative	c.1210-12T[5]
No. 21, 18 y, F	No	No	NARES	I	negative	undetected
No. 22, 17 y, M	No	No	NARESMA	I	negative	undetected
No. 23, 12 y, F	No	No	NARES	III	negative	c.1210.11T>G
No. 24, 8 y, F	No	No	NARES, asthma	III	negative	undetected
No. 25, 15 y, M	No	No	NARMA	I	negative	undetected
No. 26, 18 y, M	No	No	AR	I	negative	c.1210-12T[5]
No. 27, 18 y, M	No	No	AR, asthma	I	negative	undetected
No. 28, 18 y, M	No	No	NARESMA	I	negative	undetected
No. 29, 6 y, F	Yes§	No	AR	III	negative	c.1210-12T[5]
No. 30, 12 y, F	Yes§	No	AR	II	negative	c.1210-12T[5]
No. 31, 11 y, F	No	No	NARES, recurrent bronchitis	II	negative	undetected
No. 32, 15 y, M	No	No	NARES	I	negative	c.3485G>T
No. 33, 13 y, M	No	No	NARESMA, recurrent bronchitis	III	borderline	c.3154T>G
No. 34, 12 y, F	No	No	NARES	I	negative	c.3909C>G

List of abbreviations: No: Patient's Identification number; age in years (y); sex male (M), or female (F); CRSwNP: Chronic Rhinosinusitis with Nasal Polyps; AH: adenoidal hypertrophy; SCT: Sweat Chloride Test; CFTR: Cystic Fibrosis Transmembrane Regulator; AR: allergic rhinitis; NARMA: non allergic rhinitis with mast cells; NARES: non allergic rhinitis with eosinophils; GERD: gastroesophageal reflux disease; NARESMA: non allergic rhinitis with eosinophils and mast cells; NARNE: non allergic rhinitis with neutrophils. Legend of symbols: § Patients No. 6 and 7, 10 and 11, and 29 and 30 are brother/sister pairs.

should be promptly evaluated and managed to prevent complications. Finally, high-grade adenoid hypertrophy may contribute to the phenotypic expression of CRSwNP. A comprehensive ap-

proach to managing paediatric CRSwNP is essential, particularly considering the anticipated emergence of novel therapeutic options, such as CFTR modulator drugs ⁽⁹⁾.

Authorship contribution

Acquisition, analysis, or interpretation of data: SS, ES, GM, FC, CS, MCA. Drafts and revisions during the writing process: FM, LS, GC, RC, AGF. Final approval of the article: All the authors.

Conflict of interest

No founding sources and any commercial associations that

might pose a conflict of interest supported this work. No author has any competing interest.

Funding

This work was supported also by the Italian Ministry of Health with Current Research funds.

References

1. Heath J, Hartzell L, Putt C, Kennedy JL. Chronic rhinosinusitis in children: pathophysiology, evaluation, and medical management. *Curr Allergy Asthma Rep*. 2018 May 29;18(7):37.
2. Fokkens WJ, Lund VJ, Hopkins C, et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. *Rhinology* 2020, 58 (Suppl. 29), 1–464.
3. Hsu J, Avila PC, Kern RC, Hayes MG, Schleimer RP, Pinto JM. Genetics of chronic rhinosinusitis: state of the field and directions forward. *J Allergy Clin Immunol*. 2013 Apr;131(4):977–93, 993.e1–5.
4. Bombieri C, Claustres M, De Boeck K, et al. Recommendations for the classification of diseases as CFTR-related disorders. *J Cyst Fibros*. 2011; Suppl 2:S86–102.
5. Gonska T, Choi P, Stephenson A, et al. Role of cystic fibrosis transmembrane conductance regulator in patients with chronic sinopulmonary disease. *Chest*. 2012 Oct;142(4):996–1004.
6. Yong M, Hernaiz-Leonardo JC, Alqunae M, Quon BS, Javer A. The prevalence of CFTR mutations in patients with chronic rhinosinusitis: a systematic review and meta-analysis. *Clin Otolaryngol*. 2022; 47: 24–33.
7. Kostuch M, Klatka J, Semczuk A, Wojcierowski J, Kulczycki L, Oleszczuk J. Analysis of most common CFTR mutations in patients affected by nasal polyps. *Eur Arch Otorhinolaryngol*. 2005 Dec;262(12):982–6.
8. De Wachter E, De Boeck K, Sermet-Gaudelus I, et al. ECFS standards of care on CFTR-related disorders: towards a comprehensive program for affected individuals. *J Cyst Fibros*. 2024 May;23(3):388–397.
9. Allen L, Allen L, Carr SB, et al. Future therapies for cystic fibrosis. *Nat Commun*. 2023 Feb 8;14(1):693.

Sara Santarsiero, MD
Otorhinolaryngology Unit
Bambino Gesù Children's Hospital
Piazza Sant'Onofrio
00165 Rome
Italy

Telephone +39-32 7660 6045
E-mail: sara.santarsiero19@gmail.com
and sara.santarsiero@opbg.net

SUPPLEMENTARY MATERIAL

Materials and methods

This retrospective study analysed patients admitted to the multi-disciplinary Chronic Rhinosinusitis Allergo-Rhinologic Team ⁽¹⁾ at our hospital between September 2021 and December 2023. We included children and adolescents aged 2–18 years, diagnosed with CRSwNP based on findings from nasal endoscopy and computed tomography (CT). We investigated CFTR variants, comorbidities, and predisposing factors in the enrolled patients. Individuals with known pathologies causing CRSwNP, such as CF, primary ciliary dyskinesia (PCD), and primary immunologic disorders (PID), were excluded. We collected genetic and clinical data, and descriptive statistics were analysed using IBM® SPSS statistical software. The study design adhered to internationally recognised clinical study guidelines and was approved by the local Ethics Committee. Written assent from the young patients and informed consent from their legal guardians were obtained. Genetic testing was performed using next-generation sequencing with the Devyser CFTR Kit (Devyser®) on the MiSeq platform (Illumina®). The test sequenced the promoter, coding regions, exon-intron junctions, and intronic regions containing pathogenic variants, including c.1585-9412A>G (c.1584+18672A>G), c.1680-886A>G (1811+1.6kbA->G), and c.3718-2477C>T (3849+10kbC->T). Additionally, it analysed genomic rearrangements, such as exonic microdeletions or microduplications of the CFTR gene (NM_000492.3). The detection rate was 97%, with an analytical sensitivity and specificity of 99%. Confirmatory testing was performed through Sanger sequencing using the BigDye® Terminator v 3.1 kit and capillary electrophoresis with an automatic Genetic Analyser (Applied Biosystems). Variant nomenclature followed the Human Genome Variation Society guidelines. Identified CFTR variants were cross-referenced with major databases, including the American College of Medical Genetics and Genomics, ClinVar, CFTR2, and CFTR- France. All patients underwent the SCT, which was conducted and interpreted using standardised techniques. A chloride level ≤ 29 mmol/L was considered a normal (negative) SCT result. Levels ≥ 60 mmol/L were deemed “pathologic,” while values of 30–59 mmol/L were classified as “borderline” ⁽²⁾. We assessed patients with CFTR variants and their family members for any CFTR-RDs. All patients were evaluated for lower airway diseases through clinical chest examination, spirometry (Cosmed Micro Quark®, Italy), and in selected cases, radiologic imaging (X-ray or CT). We recorded any family history of CRSwNP as well as exposure to active or passive cigarette smoke. Adenoidal hypertrophy (AH) was assessed through nasal endoscopy and classified into grades I–IV ⁽³⁾. We also evaluated patients for allergic rhinitis (AR) and non-allergic rhinitis (NAR). Sensitisation to inhalants was determined using either a skin prick

test or a specific IgE measurement. NAR was diagnosed when nasal cytology revealed inflammatory cells in the nasal mucosa. Standardised procedures were used for sample collection, optical microscopy, and preparation of final rhinocytograms ⁽⁴⁾. NAR was further classified into four types according to the ARIA guidelines: NAR with neutrophils (NARNE), eosinophils (NARES), mast cells (NARMA), and a combination of eosinophils and mast cells (NARESMA) ⁽⁵⁾. Standard diagnostic criteria were followed for the evaluation of GERD ⁽⁶⁾.

Results

In total, 34 patients (20 males and 14 females), with a mean age of 13.41 ± 3.60 years (range: 5–18 years), were included in the study. CFTR variants were detected in 17 patients (50%). No statistically significant difference in age and sex distribution was observed between CFTR-positive and CFTR-negative patients (respectively $\chi^2 = 1.4706$, $P = 0.2252$, and $\chi^2 = 1.9429$, $P = 0.1633$). In total, 11 different CFTR variants were identified. Of these, 14 patients carried a single heterozygous variant, 2 carried 2 different heterozygous variants (Nos. 7 and 10), and 1 (No.23) was homozygous for the c.1210-11T>G variant. The intronic c.1210-12T[5] variant was present in 7 patients (Nos. 1, 2, 10, 20, 26, 29, and 30), being the most common in our series. Among these 7 patients, ages ranged from 6 to 18 years, with an approximately equal male-to-female ratio (3 males and 4 females). This variant is classified as a class V variant, resulting in reduced functional CFTR protein levels due to variable decreases in its function. Its penetrance could be modulated by other CFTR variants and environmental factors. A recent study on Chinese children with CRS also reported a high prevalence of the c.1210-12T[5] variant ⁽⁷⁾. The c.1210-12T[5], as well as the c.1210-11T>G variant, are classified as pathogenic with variable clinical consequences in CFTR-RDs (Tables S1 and S2). The c.1210-11T>G variant is another intronic variant similar to c.1210-12T[5], but involving a single nucleotide change rather than a deletion. This variant has been associated with reduced CFTR function and variable penetrance, linked to conditions, such as monosymptomatic CF, CFTR-RDs, and NPs (Tables S1 and S2). The c.3322G>C variant was detected in 2 patients, a 12-year-old female (No. 6) and a 9-year-old male (No. 7), who also carried the c.3705T>G variant. Both the c.3322G>C and c.3705T>G variants are classified as variants of uncertain significance (VUS) due to limited database information. Recently c.3705T>G and c.91C>T have been classified as exonic missense variants of class IV, associated with defective ion conductance in the CFTR channel (Tables S1 and S2). Han et al. ⁽⁷⁾ reported high expression of c.91C>T in children with CRS, suggesting an increased risk of

the disease. The c.91C>T variant was identified in 2 patients, an 18-year-old female (No. 9) and a 14-year-old male (No. 16). This variant is classified as VUS class 4 (VUS4), having been associated with CFTR-RDs and some CF cases. Ten additional variants were identified across all groups (Table S1). Further details along with database links for all CFTR variants are provided in Table S2. Borderline SCT results were observed in 3 patients. A 10-year-old male (No. 10) with 2 HEZ CFTR variants (c.1210-12T[5] and c.1736A>G) showed borderline results, as did a 13-year-old male (No. 1) with the c.1210-12T[5] variant, and a 13-year-old male (No. 33) who carried the c.3154T>G variant.

None of the patients or their families had a diagnosis of CBAVD, RP, or DB. Although not statistically significant, patients with CFTR variants exhibited a higher incidence of lower airway disease compared to CFTR-negative patients (47.06% vs. 29.41%, $\chi^2 = 1.1209$, $P = 0.2896$). Among CFTR-positive patients, asthma was diagnosed in 5 patients, whereas recurrent bronchitis was identified in 3 others. In contrast, asthma was diagnosed in only 2 CFTR-negative patients (29.41% vs 11.76%, $\chi^2 = 1.619$, $P = 0.2032$), while chronic bronchitis was also present in 3 CFTR-negative patients.

A family history of CRSwNP was reported in 6 patients, involving 3 sibling pairs (Nos. 6 and 7, Nos. 10 and 11, and Nos. 29 and 30). None of their parents or other relatives had CRSwNP. Four patients were passively exposed to cigarette smoke, including an 18-year-old female (No. 9) with asthma and the c.91C>T variant, and 3 CFTR-negative patients (Nos. 5, 15, and 19). Nasal endoscopy revealed significant adenoid hypertrophy (grades III and IV) in 8 CFTR-positive and 2 CFTR-negative patients

(47.06% vs. 11.76%, $\chi^2 = 5.1$, $P = 0.0239$). AR was diagnosed in 9 CFTR-positive and 7 CFTR-negative patients, with no statistically significant difference observed (52.94% vs 41.18%). NAR was identified in all non-allergic patients in both groups (47.06% vs. 58.82%), with no significant difference. NARES (8 patients, 3 CFTR-positive and 5 CFTR-negative) and NARESMA (8 patients, 4 CFTR-positive and 4 CFTR-negative) were the most common types of NAR. NARMA was detected in 1 patient from each group, whereas NARNE was not identified. GERD was diagnosed in two 12-year-old girls with CRSwNP, AR, and CFTR variants. One of these patients, who carried the c.3322G>C variant, also had asthma, while the other patient had the c.1210-12T[5] variant.

Conclusions

Defining the role of CFTR variants in pediatric CRSwNP is crucial for future perspectives. To better define the pathogenetic role of these genetic background, proteomic and transcriptomic studies will be desirable. Furthermore, studies on a larger sample should be carried out considering the different incidence of CFTR variants in different ethnies and countries, and the significant impact of the environment on genetic expression.

In recent years, CFTR modulators have emerged as the standard of care for CF-affected patients. These mutation-specific therapies restore CFTR protein function, leading to significant improvements in clinical outcomes, including for CRSwNP patients. Although currently indicated for patients with at least one F508del CFTR mutation, the potential benefits of these modulators extend to individuals with other CFTR variants that impair protein function⁽⁸⁾.

References

1. Sitzia E, Santarsiero S, Marini G, et al. Endotypes of Nasal Polyps in Children: A Multidisciplinary Approach. *J Pers Med*. 2023;13(5):707.
2. <https://www.cff.org/medical-professionals/sweat-test-clinical-care-guidelines-2>, accessed December 9th, 2024.
3. Parikh SR, Coronel M, Lee JJ, Brown SM. Validation of a new grading system for endoscopic examination of adenoid hypertrophy. *Otolaryngol Head Neck Surg*. 2006;135(5):684-687.
4. Gelardi M, Cavaliere C, Jannuzzi L. Nasal cytology. *J Biol Regul Homeost Agents*. 2018;32(1 Suppl. 1):37-40.
5. Wise SK, Damask C, Roland LT, et al. International consensus statement on allergy and rhinology: Allergic rhinitis - 2023. *Int Forum Allergy Rhinol*. 2023;13(4):293-859.
6. Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and
7. Han Y, Zhao J, Liu W, et al. Increased prevalence of CFTR variants and susceptibility to CRS: A real-world study based on Chinese children. *Heliyon*. 2024;10(7):e27681.
8. Allen L, Allen L, Carr SB, et al. Future therapies for cystic fibrosis. *Nat Commun*. 2023;14(1):693.

Table S1. CFTR variants in 17 patients with CRSwNP: classification and clinical correlations in different databases.

Patient's No, age (y), sex	HGVS nomenclature	Allele frequency [§]	ACMG 2015 classification	ClinVar database *	CFTR2 database	CFTR-France database	Clinical conditions associated in literature
No. 1, 13y, M	c.1210-12T[5] (HEZ)	GMAF: 0.02316 (TTTTT)	Pathogenic/Likely Pathogenic	Pathogenic (13); Likely pathogenic (1); Uncertain significance (2); Likely benign (1)	VVCC	VVCC	CBAVD; bronchiectasis (with or without elevated SCT); CF; CFTR-RD; OZ; HP.
No. 2, 9y, F	c.1210-12T[5] (HEZ)	GMAF: 0.02316 (TTTTT)	Pathogenic/Likely Pathogenic	Pathogenic (13); Likely pathogenic (1); Uncertain significance (2); Likely benign (1)	VVCC	VVCC	CBAVD; bronchiectasis (with or without elevated SCT); CF; CFTR-RD; OZ; HP.
No. 6, 12y, F	c.3322G>C (p.Val1108Leu; legacy: V1108L) (HEZ)	GMAF: - gnomAD, TOPMed: 0.0002	VUS	Uncertain significance (7)	Not found	VUS2	CF; CFTR-RD
No. 7, 9y, M	c.3322G>C (p.Val1108Leu; legacy: V1108L) (HEZ)	GMAF: - gnomAD, TOPMed: 0.0002	VUS	Uncertain significance (7)	Not found	VUS2	CF; CFTR-RD
	c.3705T>G (p.Ser1235Arg; legacy: S1235R) (HEZ)	GMAF: - gnomAD: 0.00573 TOPMed: 0.00526 NHLBI ESP: 0.00577	VUS	Uncertain significance (3); Benign (6); Likely benign (5)	Non-CF causing		CF; CFTR-RD; OZ; HP; CBAVD
No. 9, 18y, F	c.91C>T (p.Arg31Cys; legacy: R31C) (HEZ)	GMAF: 0.00140 (T); gnomAD: 0.00134; TOPMed: 0.00147; NHLBI ESP: 0.00077	VUS	Uncertain significance (9); Benign (3); Likely benign(4)	Non-CF causing		CF; bronchiectasis (with or without elevated SCT); CFTR-RD; HP; CBAVD
No. 10, 10y, M	c.1210-12T[5] (HEZ)	GMAF: 0.02316 (TTTTT)	Pathogenic/Likely Pathogenic	Pathogenic (13); Likely pathogenic (1); Uncertain significance (2); Likely benign (1)	VVCC	VVCC	CBAVD; bronchiectasis (with or without elevated SCT); CF; CFTR-RD; OZ; HP.
	c.1736A>G (p.Asp579Gly; legacy: D579G) (HEZ)	GMAF: - gnomAD: 0.00000	Pathogenic	Drug Response (1); Pathogenic (12)	VVCC	VVCC	CF; CBAVD; CFTR-RD; ivacaftor response – efficacy; bronchiectasis (with or without elevated SCT).
No. 11, 5y, F	c.2991G>C (p.Leu997Phe; legacy: L997F) (HEZ)	GMAF: 0.00180 (C) gnomAD: 0.00208 TOPMed: 0.00262	VUS	Pathogenic (4); Likely pathogenic(1); Uncertain significance(11); Benign(2); Likely benign(1)	Non-CF causing	CFTR-RD-causing	Susceptibility to idiopathic pancreatitis, and neonatal hypertrypsinemia; CF; pancreatitis; CFTR-RD; ID ; OA.
No. 16, 14y, M	c.91C>T (p.Arg31Cys; legacy: R31C) (HEZ)	GMAF: 0.00140 (T); gnomAD: 0.00134; TOPMed: 0.00147; NHLBI ESP: 0.00077	VUS	Uncertain significance (9); Benign (3); Likely benign(4)	Non-CF causing	VUS4	CF; bronchiectasis (with or without elevated SCT); CFTR-RD; HP; CBAVD
No. 18, 18y, M	c.2900T>C (p.Leu967Ser; legacy: L967S) (HEZ)	GMAF: 0.00040 (C) NHLBI ESP: 0.00038 TOPMed: 0.00104 gnomAD: 0.00106	Likely Pathogenic	Pathogenic (1); Likely pathogenic(3); Uncertain significance(15)	VVCC	VUS2	CF; ID; bronchiectasis (with or without elevated SCT); CFTR-RD; HP.
No. 20, 14y, F	c.1210-12T[5] (HEZ)	GMAF: 0.02316 (TTTTT)	Pathogenic/Likely Pathogenic	Pathogenic (13); Likely pathogenic (1); Uncertain significance (2); Likely benign (1)	VVCC	VVCC	CBAVD; bronchiectasis (with or without elevated SCT); CF; CFTR-RD; OZ; HP.

Patient's No, age (y), sex	HGVS nomenclature	Allele frequency [§]	ACMG 2015 classification	ClinVar database *	CFTR2 database	CFTR-France database	Clinical conditions associated in literature
No. 23, 12y, F	c.1210.11T>G (HOZ)	GMAF: - gnomAD: 0.00886 NHLBI ESP: 0.00331	Pathogenic	Pathogenic(12); Likely pathogenic(2); Uncertain significance(2)	VVCC	Not found	CBAVD; bronchiectasis (with or without elevated SCT); CF; CFTR-RD
No. 26, 18y, M	c.1210-12T[5] (HEZ)	GMAF: 0.02316 (TTTTT)	Pathogenic/Likely Pathogenic	Pathogenic (13); Likely pathogenic (1); Uncertain significance (2); Likely benign (1)	VVCC	Varying clinical consequence	CBAVD; bronchiectasis (with or without elevated SCT); CF; CFTR-RD; OZ; HP.
No. 29, 6y, F	c.1210-12T[5] (HEZ)	GMAF: 0.02316 (TTTTT)	Pathogenic/Likely Pathogenic	Pathogenic (13); Likely pathogenic (1); Uncertain significance (2); Likely benign (1)	VVCC	Varying clinical consequence	CBAVD; bronchiectasis (with or without elevated SCT); CF; CFTR-RD; OZ; HP.
No. 30, 12y, F	c.1210-12T[5] (HEZ)	GMAF: 0.02316 (TTTTT)	Pathogenic/Likely Pathogenic	Pathogenic (13); Likely pathogenic (1); Uncertain significance (2); Likely benign (1)	VVCC	Varying clinical consequence	CBAVD; bronchiectasis (with or without elevated SCT); CF; CFTR-RD; OZ; HP.
No. 32, 15y, M	c.3485G>T (p.Arg1162Leu; legacy: R1162L)	GMAF: 0.00080 (T) NHLBI ESP: 0.00062 TOPMed: 0.00063	VUS	Pathogenic (2); Likely pathogenic (2); Uncertain significance (5); Benign (2); Likely benign (3)	Non-CF causing	CFTR-RD-causing	CF; CFTR-RD; OZ.
No. 33, 13y, M	c.3154T>G (p.Phe1052Val; legacy: F1052V)	GMAF: - gnomAD: 0.00039 TOPMed: 0.00079 NHLBI ESP: 0.00100	VUS	Uncertain significance (12); Drug Response (1); Pathogenic (4)	VVCC	CFTR-RD-causing	CF; ivacaftor response – efficacy; HP; CBAVD; CFTR-RD; bronchiectasis (with or without elevated SCT).
No. 34, 12y, F	c.3909C>G (p.Asn1303Lys; legacy: N1303K)	GMAF: 0.00020 (G) gnomAD: 0.00016 TOPMed: 0.00020	Pathogenic	Pathogenic (40)	CF-causing#	CF-causing	CF; CBAVD; Y-linked spermatogenic failure; CFTR-RD; HP; bronchiectasis (with or without elevated SCT).

List of abbreviations: No: Patient's Identification number; age in years (y); sex male (M), or female (F); ACMG: American College of Medical Genetics; HGVS: Human Genome Variation Society; CFTR: Cystic Fibrosis Transmembrane Regulator; CRSwNP: Chronic Rhinosinusitis with Nasal Polyps; HEZ: Heterozygous; GMAF: Global Minor Allele Frequency; VVCC: Variant of Varying Clinical Consequence; CBAVD: Congenital Bilateral Aplasia of Vas Deferens; SCT: Sweat Chloride Test; CF: Cystic Fibrosis; CFTR-RD: CFTR-Related Disorders; gnomAD: Genome Aggregation Database; TOPMed: Trans-Omix for Precision Medicine; HOZ: Homozygous; HP: Hereditary pancreatitis; VUS: Variant of Uncertain Significance; ID: infertility disorder; OA: Obstructive Azoospermia; NHLBI: National Heart, Lung, and Blood Institute; ESP: Exome Variant Server. Legend of symbols: § From ClinVar database; reference sequence: NM_000492.3. * In case of conflicting classification of pathogenicity, the number of the studies reporting the evidence is in brackets. # When combined with another CF-causing variant.

Table S2. Links to the databases of CFTR mutations are provided for each variant.

CFTR variant	ClinVar database	CFTR2 database	CFTR France database
c.1210-12T[5]	https://www.ncbi.nlm.nih.gov/clinvar/variation/242535/	https://cftr2.org/mutation/general/5T/ ; https://cftr2.org/mutation/general/5T%253BTG12	https://cftr.iurc.montp.inserm.fr/cgi-bin/affiche.cgi?variant=c.1210-12T%5B5%5D
C.3322G>C	https://www.ncbi.nlm.nih.gov/clinvar/variation/53719/	not found	https://cftr.iurc.montp.inserm.fr/cgi-bin/affiche.cgi?variant=c.3322G%3EC
c.3705T>G	https://www.ncbi.nlm.nih.gov/clinvar/variation/35872/?oq=c.3705T%3EG[varname]+CFTR&m=NM_000492.4(CFTR):c.3705T%3EG%20(p.Ser1235Arg)	https://cftr2.org/mutation/general/S1235R/	https://cftr.iurc.montp.inserm.fr/cgi-bin/affiche.cgi?variant=c.3705T%3EG
c.91C>T	https://www.ncbi.nlm.nih.gov/clinvar/variation/35894/?oq=c.91C%3ET[varname]+CFTR&m=NM_000492.4(CFTR):c.91C%3ET%20(p.Arg31Cys)	https://cftr2.org/mutation/general/R31C/	https://cftr.iurc.montp.inserm.fr/cgi-bin/affiche.cgi?variant=c.91C%3ET
c.1736A>G	https://www.ncbi.nlm.nih.gov/clinvar/variation/53365/?oq=c.1736A%3EG[varname]+CFTR&m=NM_000492.4(CFTR):c.1736A%3EG%20(p.Asp579Gly)	https://cftr2.org/mutation/general/D579G/	https://cftr.iurc.montp.inserm.fr/cgi-bin/affiche.cgi?variant=c.1736A%3EG
c.2991G>T	https://www.ncbi.nlm.nih.gov/clinvar/variation/7229/?oq=c.2991G%3EC[varname]+CFTR&m=NM_000492.4(CFTR):c.2991G%3EC%20(p.Leu997Phe)	https://cftr2.org/mutation/general/L997F/	https://cftr.iurc.montp.inserm.fr/cgi-bin/affiche.cgi?variant=c.2991G%3EC
c.2900T>C	https://www.ncbi.nlm.nih.gov/clinvar/variation/219537/?oq=c.2900T%3EC[varname]+CFTR&m=NM_000492.4(CFTR):c.2900T%3EC%20(p.Leu967Ser)	https://cftr2.org/mutation/general/L967S/	https://cftr.iurc.montp.inserm.fr/cgi-bin/affiche.cgi?variant=c.2900T%3EC
c.1210-11T>G	https://www.ncbi.nlm.nih.gov/clinvar/variation/178713/	https://cftr2.org/mutation/general/5T%253BTG12/	not found
c.3485G>T	https://www.ncbi.nlm.nih.gov/clinvar/variation/256253/?oq=c.3485G%3ET[varname]+CFTR&m=NM_000492.4(CFTR):c.3485G%3ET%20(p.Arg1162Leu)	https://cftr2.org/mutation/general/R1162L/	https://cftr.iurc.montp.inserm.fr/cgi-bin/affiche.cgi?variant=c.3485G%3E
c.3154T>G	https://www.ncbi.nlm.nih.gov/clinvar/variation/35865/?oq=c.3154T%3EG[varname]+CFTR&m=NM_000492.4(CFTR):c.3154T%3EG%20(p.Phe1052Val)	https://cftr2.org/mutation/general/F1052V/	https://cftr.iurc.montp.inserm.fr/cgi-bin/affiche.cgi?variant=c.3154T%3EG
c.3909C>G	https://www.ncbi.nlm.nih.gov/clinvar/variation/7136/?oq=c.3909C%3EG[varname]+CFTR&m=NM_000492.4(CFTR):c.3909C%3EG%20(p.Asn1303Lys)	https://cftr2.org/mutation/general/N1303K/	https://cftr.iurc.montp.inserm.fr/cgi-bin/affiche.cgi?variant=c.3909C%3EG